DDL2021 Programme

Please Note: The DDL2021 Presentation Timings are in GMT / UK time

11:00

Conference Opens

11:00 - 11:05

Welcome to the DDL2021 Conference

An introduction to the conference by the DDL Conference Chair

Introducing the DDL Annual Lecture

Gary Pitcairn, DDL Chair

11:05 - 11:35

Digitalisation in respiratory medicine, where are we heading to?

DDL Annual Lecture

Dr. Sabine Häussermann, VisionHealth GmbH

The DDL Lecture is a prestigious accolade bestowed on individuals who have contributed much to the field of respiratory science.

11:35 - 11:40

Introduction to our Invited Speaker

11:40 - 12:05

Changes in GINA asthma management – What this means for treating patients with asthma?

Professor David Price, Observational and Pragmatic Research Institute & University of Aberdeen

12:05 - 12:15

Refreshment Break

12:15 - 12:20

Introduction to our Invited Speakers

12:20 - 12:45

Considerations of Inhaler User-life in Clinical Practice

Dr Roy Pleasants, University of North Carolina

12:45 - 13:10

Inhaled therapies for COVID-19

Professor Peter Barnes, National Heart & Lung Institute, Imperial College London

13:10 - 13:40

Refreshment Break

13:40 - 13:45

Introduction to the FLASH presenters and the Interactive Discussion Forum

13:45 - 13:55

Targeting Deep Lungs with Swellable Nano/Microgels for the Delivery of Suramin

David Encinas, University of Arizona

13:55 - 14:05

Improving Physical and Aerosol Stability of Spray Dried High-dose Dry Powder Inhaler Formulations

Nivedita Shetty, Genentech Inc.,

14:05 - 14:15

Spray-congealing and wet-sieving as alternative processes for the engineering of D-mannitol carriers

Joana Pinto, Research Center Pharmaceutical Engineering GmbH

14:15 - 15:15

Interactive Discussion Forum

Hosted by the DDL New Researcher Network Committee

Delegates are invited to interact with the FLASH presenters of the preceding talks, asking questions and debating the day’s topics.

15:15

End of Day 1

11:00

Conference Opens

11:00 - 11:05

Introduction to the Pat Burnell Young Investigator Award Finalists

This award recognises the vision of Pat Burnell and has been designed

to encourage junior researchers from either academia or industry to

present their work at the DDL Conference.

11:05 - 11:20

Investigating the Effects of Fluid Composition on Bacterial Aerosol Production

Mathura Thirugnanasampanthar, McMaster University

11:20 - 11:35

An adaptable dual-chamber microfluidic platform to investigate Pseudomonas aeruginosa biofilm growth at the air-liquid interface under controlled hydro and aerodynamic flows

Ye Zhang, Woolcock Institute of Medical Research

11:35 - 11:50

Pulmonary delivery of bedaquiline-loaded cubosomes for non-small cell lung cancer (NSCLC) treatment

Suyash Patil, St. John’s University

11:50 - 12:05

A human nose-on-a-chip as a physiologically relevant in-vitro model for nasal drug delivery

Hanieh Gholizadeh, Woolcock Institute of Medical Research

12:05 - 12:20

Refreshment Break

12:20 - 12:25

Introduction to our Invited Speakers

12:25 - 12:50

Pre-clinical animal models: useful asset or a waste of resources?

Dr Mark Birrell, AstraZeneca & Imperial College London

12:50 - 13:15

Functional Respiratory Imaging in times of COVID19

Jan de Backer, FLUIDDA

13:15 - 13:45

Refreshment Break

13:45 - 13:50

Introduction to the FLASH presenters and the Interactive Discussion Forum

13:50 - 14:00

Using microscopic high-speed imaging to quantify agglomerate-to-wall impaction in dry powder inhalers

Athiya Azeem, University of Sydney

14:00 - 14:10

A Propellant Dispersible Tablet for Preparation of Salmeterol/Fluticasone Combination pMDIs using Low-GWP HFC152a

Cuong H Tran, i2c Pharmaceutical Services

14:10 - 14:20

Effects of Realistic In Vitro Test Factors on the Aerosol Properties of Metered-Dose Inhalers (MDIs)

Sneha Dhapare, Food and Drug Administration

14:20 - 15:20

Interactive Discussion Forum

Hosted by the DDL New Researcher Network Committee

Delegates are invited to interact with the FLASH presenters of the preceding talks, asking questions and debating the day’s topics.

15:20

End of Day 2

11:00

Conference Opens

11:00 - 11:05

Announcing the Winner of the Pat Burnell Young Investigator Award

11:05 - 11:10

Introducing the Emerging Scientist 2021 Winner

This award recognises significant scientific accomplishment or innovation during the early stages of an individual’s career in inhalation science.

11:10 - 11:40

Presentation by the DDL Emerging Scientist 2021 Winner

The winner of this award will present a live lecture based on the research synopsis they submitted as part of their application.

11:40 - 11:45

Introduction to our Invited Speaker

11:45 - 12:10

Inhalers and the tobacco industry – implications for practice, prescribers and patients

Dr Toby Capstick, Leeds Teaching Hospitals NHS Trust

12:10 - 12:25

Refreshment Break

12:25 - 12:30

Introduction to our Invited Speakers

12:30 - 12:55

Targeted Nasal Drug Delivery – for Nose, Body and Brain

Dr Julie Suman, Next Breath, an Aptar Pharma company

12:55 - 13:20

Nebulizers and COVID-19: Aerosol Generation vs. Aerosol Dispersion

Dr. Rajiv Dhand, University of Tennessee

13:20 - 13:50

Refreshment Break

13:50 - 13:55

Introduction to the FLASH presenters and the Interactive Discussion Forum

13:55 - 14:05

High-dose inhaled rifampicin powder formulations: preparation, in vitro characterization and in vivo evaluation

Prakash Khadka, University of Otago

14:05 - 14:15

Respirable powder containing Cyclosporine A loaded liposomes as immunosuppressive agent suitable for lung transplant rejection and the containment of severe lung inflammation

Davide D’Angelo, University of Parma

14:15 - 14:25

Protein DPI production: discriminating destabilising influences during spray drying

Friederike Roth, University of Kiel

14:25 - 15:25

Interactive Discussion Forum

Hosted by the DDL New Researcher Network Committee

Delegates are invited to interact with the FLASH presenters of the preceding talks, asking questions and debating the day’s topics.

15:25

Close of Conference

1

Inhalable cannabidiol dry powders with enhanced solubility

Waiting Tai, The University of Sydney

2

Developing Analytical Methodology and Test Apparatus to Study Drug Deposition in the Throat

Matthew Potts, Kindeva Drug Delivery Ltd

3

HFA-152a Inhaler Dose Release

Alan McKiernan, Prior PLM Medical

4

Towards a More Realistic Method for Measuring Nebulized Aerosols: Measurement of Fine Particle Fraction During Simulated Adult Breathing with a Nephele Mixing Inlet and Laser Diffraction with Simultaneous Drug Dose Analysis

Lois Slator, Philips

5

In Vitro Investigation into Fugitive Aerosol from a Novel 4th Generation Adaptive Aerosol Delivery (AAD) System

Adam Metcalf, Philips

6

Aerodynamic particle size distribution and delivered dose efficiency of a continuous-output mesh nebuliser and a novel breath-actuated device using terbutaline sulphate

Hernan Cuevas Brun & Huei-An Tsai , HCmed Innovations Co., Ltd.

7

Is a Pressure Drop ≥10 cm H2O with any Dry Powder Inhaler (DPI) a Reasonable Threshold Above which a Patient Should Receive an Adequate Lung Dose: Method Validation and Experience with a Sample Cohort of COPD Patients?

Mark Nagel, Trudell Medical International

8

Effect of an inhalation chamber without inspiratory valve and facemask for neonates use on drug delivery.

Brenda Hervieu, OptimHal-ProtecSom

9

Machine Learning approach to predict the formation co-amorphous systems for inhalation therapy

Sarah Zellnitz, Research Center Pharmaceutical Engineering GmbH

10

Investigation of design features on the performance of 3D-printed dry powder inhalers. Part 1: grid mesh

Yuqing Ye, University of Western Ontario

11

Determination of an appropriate dose ratio of a synergistic combination of long-acting bronchodilators for the maintenance treatment of asthma and COPD

Elena Menchi, Université libre de Bruxelles

12

A Predictive Model To Explore The Effects Of Physicochemical Properties On Mesh-Nebulisation

Annabel Flook, University of Bath

13

Identification of potential antioxidant degradation products as Extractables from an innovative Thermo Plastic Elastomer used in Metered Dose Inhalers

Claire Cannette, Aptar Pharma Company

14

Understanding impact of fines on flow behavior of lactose blends with and without magnesium stearate and its impact on filling using membrane filling technology

Mohit Mehta, Harro Höfliger Verpackungsmaschinen GmbH

15

Influence of material and capsule filling process with Minima® on aerosolization performances by DPIs

Annalisa Bianchera, University of Parma

16

Co-amorphization: A formulation strategy for amorphous high dose dry powder to treat lung infections

Bishal Adhikari, University of Otago

17

Budesonide Solution MDIs: Plasma Treated Canister Performance and other Canister Types

David Lewis, Oz-UK Limited

18

Fluticasone Propionate Suspension MDIs: Plasma Treated Canister Performance and other Canister Types

David Lewis, Oz-UK Limited

19

A Design of Experiments approach to optimising spray drying yield and production efficiency of a model inhaled powder for global health applications

Andrew McArthur, Monash University

20

Formulation, Characterization and Optimization of Dry Powder for Inhalation using combined micronized Levo-Dropropizine and Curcumin

Carlotta Giulieri, Perugia University and Formulation Scientist of Cosmo Pharma.

21

Fundamental properties of propellant aerosols can guide transition to low global warming potential pMDIs: size, velocity and surface charge

Irene​ Rossi & William J Ganley, Nanopharm, an Aptar Pharma Company

22

Investigation on the impact of resonant acoustic mixing parameters and carrier type on the deposition patterns of Budesonide/Formoterol Fumarate DPI combination product

Snezana Radivojev, Research Center Pharmaceutical Engineering GmbH; Medical University of Graz

23

A high force pMDI for delivery into the olfactory region of the nasal cavity

Andy Cooper, Kindeva Drug Delivery

24

The application of morphological filters in automated imaging for nasal formulations: a design of experiment approach

Paulo​ Serra, Nanopharm, an Aptar Pharma Company

25

Device and Formulation Factors affecting the Aerosol Performance of Pressurised Metered Dose Inhalers

 

Benjamin Thorne, University of Hertfordshire

26

Development of a nasal spray containing a novel human recombinant antibody for SARS-CoV-2 therapy

Antonia Zapata del Baño, Nanopharm, an Aptar Pharma Company

27

How does the Tongue Influence Transport of Inhaled Particles from a Pressurized Metered Dose Inhaler (pMDI) and Valved Holding Chamber (VHC)

Mark Nagel, Trudell Medical International

28

Leveraging DPI formulation screening: particle-particle interaction

Raquel Borda d’ Água & João Pereira, Hovione

29

Plume Front Velocity and Force to Actuation Characterisation of Pressurised Metered Dose Inhalers and Soft Mist Inhalers  

Miles Jeanneret, Intertek Melbourn

30

WITHDRAWN

31

Influence of Geography on the Carbon Footprint Impact of Breezhaler® Dry Powder Inhaler

Simon Aumônier, Environmental Resources Management

32

The Quantitative Assessment of Vape Devices as Novel Pulmonary Drug Delivery Systems Using Fluorine-18 Radiolabelled Drug Molecules

George Herbert, The University of Hull

33

Enabling Pulmonary Drug Delivery with Nanoporous Particles

Irès van der Zwaan, Uppsala University

34

In vitro and in vivo evaluations of the tolerance of a new and innovative anti-tuberculosis drug combination by inhalation

Faustine Ravon, Université Libre de Bruxelles

35

Transport of Local Anaesthetic Lidocaine across a Pharyngeal Air-Liquid Interface Cell Model  

Zara Sheikh, Woolcock Institute of Medical Research

36

Formulation Development of Inhalable Dacomitinib Polymeric Nanoparticles for Non-Small Cell Lung Cancer Treatment

Sarika Druva Barji, St. John’s University

37

Nasal-PAMPA: a novel in vitro tool for prediction of intranasal drug permeability

Patrícia Henriques,  Hovione and University of Coimbra

38

Surface Acoustic Wave Nebulisation for Targeted Inhalation Drug Delivery to Central and Peripheral Airways

Elijah Nazarzadeh, Acu-Flow Limited

39

The evolution of unsteady flow from dry powder inhalers

Vishal Chaugule, Monash University

40

Assessment of aerosol drug delivery during the escalation of treatment for a simulated     COVID-19 adult patient

Ronan MacLoughlin, Aerogen Limited

41

Development of a prototype of an aerosolization device for dry powders to improve in vitro cell-based assays in the context of lung delivery

Jorge Pontes, Universidade do Algarve